alexa
Reach Us +1-947-333-4405
Rhodiola Rosea Therapy for Major Depressive Disorder: A Study Protocol for a Randomized, Double-Blind, Placebo- Controlled Trial | OMICS International | Abstract
ISSN: 2167-0870

Journal of Clinical Trials
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Protocol

Rhodiola Rosea Therapy for Major Depressive Disorder: A Study Protocol for a Randomized, Double-Blind, Placebo- Controlled Trial

Jun J Mao1,2,3*, Qing S Li1, Irene Soeller1, Sharon X Xie2 and Jay D Amsterdam4
1Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
2Center for Clinical Epidemiology and Biostatistics and Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
3Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
4Depression Research Unit, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
Corresponding Author : Jun J Mao, MD, MSCE
Department of Family Medicine and Community Health
University of Pennsylvania, 227 Blockley Hall
423 Guardian Drive, Philadelphia, Pennsylvania 19104, USA
Tel: 215-746-2481
Fax: 215-662-3591
E-mail: [email protected]
Received May 13, 2014; Accepted June 18, 2014; Published June 20, 2014
Citation: Mao JJ, Li QS, Soeller I, Xie SX, Amsterdam JD (2014) Rhodiola Rosea Therapy for Major Depressive Disorder: A Study Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Trials 4:170. doi:10.4172/2167-0870.1000170
Copyright: © 2014 Mao JJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Rhodiola rosea (R. rosea), a botanical of both western and traditional Chinese medicine, has been used as a folk remedy for improving stamina and reducing stress. However, few controlled clinical trials have examined the safety and efficacy of R. rosea for the treatment of major depressive disorder (MDD). This study seeks to evaluate the safety and efficacy of R. rosea in a 12-week, randomized, double-blind, placebo-controlled, parallel group study design.
Methods/Design: Subjects with MDD not receiving antidepressant therapy will be randomized to either R. rosea extract 340-1,360 mg daily; sertraline 50-200 mg daily, or placebo for 12 weeks. The primary outcome measure will be change over time in the mean 17-item Hamilton Depression Rating score. Secondary outcome measures will include safety and quality of life ratings. Statistical procedures will include mixed-effects models to assess efficacy for primary and secondary outcomes.
Discussion: This study will provide valuable preliminary information on the safety and efficacy data of R. rosea versus conventional antidepressant therapy of MDD. It will also inform additional hypotheses and study design of future, fully powered, phase III clinical trials with R. rosea to determine its safety and efficacy in MDD.

Keywords

Recommended Conferences
Share This Page
Top